We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · March 27, 2021

Vandetanib in Previously Treated Patients With RET-Rearranged Advanced NSCLC

Lung Cancer


Additional Info

Disclosure statements are available on the authors' profiles:

Lung Cancer
Final Survival Results for the LURET Phase II Study of Vandetanib in Previously Treated Patients With RET-Rearranged Advanced Non-Small Cell Lung Cancer
Lung Cancer 2021 Mar 10;155(xx)40-45, K Yoh, T Seto, M Satouchi, M Nishio, N Yamamoto, H Murakami, N Nogami, K Nosaki, T Kohno, K Tsuta, S Nomura, T Ikeno, M Wakabayashi, A Sato, S Matsumoto, K Goto

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading